title: Amgen swallows Micromet to BiTE into ALL market.
authors.forename: Cormac
authors.initials: C
authors.lastname: Sheridan
mesh_terms: D018033:Antibodies, Bispecific / Q000191:economics* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic / Q000191:economics; D004345:Drug Industry / Q000191:economics; D006801:Humans; D007167:Immunotherapy / Q000191:economics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000191:economics* / Q000628:therapy
chemical_list: D018033:Antibodies, Bispecific; C510808:blinatumomab